Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice

被引：0
作者：
Beung-Chul Ahn
Kyoung-Ho Pyo
Chun-Feng Xin
Dongmin Jung
Hyo Sup Shim
Chang Young Lee
Seong Yong Park
Hong In Yoon
Min Hee Hong
Byoung Chul Cho
Hye Ryun Kim
机构：
[1] Yonsei University College of Medicine,Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center
[2] Yonsei University College of Medicine,Severance Biomedical Science Institute
[3] Yonsei University College of Medicine,Department of Pathology, Severance Hospital
[4] Yonsei University College of Medicine,Department of Thoracic and Cardiovascular Surgery
[5] Yonsei University College of Medicine,Department of Radiation Oncology, Yonsei Cancer Center
来源：
Journal of Cancer Research and Clinical Oncology | 2019年 / 145卷
关键词：
Immunotherapy; Non-small cell lung cancer; Real-world setting; PD-1; Survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1613 / 1623
页数：10
相关论文
共 68 条
  • [1] Borghaei H(2015)Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N Engl J Med 373 1627-1639
  • [2] Brahmer J(2015)Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 373 123-135
  • [3] Eisenhauer EA(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-247
  • [4] Freeman-Keller M(2016)Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes Clin Cancer Res 22 886-894
  • [5] Kim Y(2016)Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review JAMA Oncol 2 1346-1353
  • [6] Cronin H(2018)Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: a multicenter retrospective cohort study Lung Cancer (Amst, Neth) 119 14-20
  • [7] Richards A(2018)Italian nivolumab expanded access program in nonsquamous non-small cell lung cancer patients: results in never-smokers and EGFR-mutant patients J Thorac Oncol 13 1146-1155
  • [8] Gibney G(2017)Thoracic oncology clinical trial eligibility criteria and requirements continue to increase in number and complexity J Thorac Oncol 12 1489-1495
  • [9] Weber JS(2015)Pembrolizumab for the treatment of non-small-cell lung cancer N Engl J Med 372 2018-2028
  • [10] Friedman CF(2018)Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases Lung Cancer (Amst, Neth) 116 62-66
1234567